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and recurrent AF after cardioversion or catheter ablation. A
proarrhythmic effect of inflammation may explain why non-
antiarrhythmic agents that have anti-inflammatory effects,
including statins and fish oil, have been shown to prevent
AF in some studies.   
Summary written by: Fred Morady, MD
Periprocedural Stroke and Management of Major
Bleeding Complications in Patients Undergoing
Catheter Ablation of Atrial Fibrillation. The Impact
of Periprocedural Therapeutic International
Normalized Ratio
Di Biase L, Burkhardt JD, Mohanty P, et al.
Circulation 2010;121:2550-2556.
Study Question: What is the impact of a therapeutic interna-
tional normalized ratio (INR) on stroke and bleeding
complications during radiofrequency catheter ablation
(RFCA) of atrial fibrillation (AF)? 
Methods: A total of 6,454 patients (mean age 57 years)
underwent RFCA of AF at nine centers. The patients were
classified as: group I: 8-mm-tip ablation catheter, off war-
farin (n = 2,488); group II: open irrigated-tip catheter, off
warfarin (n = 1,348); and group III: open irrigated-tip
catheter, on warfarin with INR >2 (n = 2,618). Heparin was
used in all groups to maintain an activated clotting time
>350 seconds.
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A Multimarker Approach to Assess the Influence
of Inflammation on the Incidence of Atrial
Fibrillation in Women 
Conen D, Ridker PM, Everett BM, et al. 
Eur Heart J 2010;May 25:[Epub ahead of print].
Study Question: Does inflammation promote atrial fibrillation
(AF) in women?
Methods: Study subjects were 24,734 women (median age 53
years) free of cardiovascular disease and AF at entry followed
for a median of 14.4 years. Blood samples at entry were ana-
lyzed for three biomarkers of inflammation: C-reactive
protein, soluble intercellular adhesion molecule-1, and fibrin-
ogen. An inflammation score of 0-3 was used to indicate the
number of biomarkers in the highest tertile per individual.
Results: A first episode of AF occurred in 3% of women. Each
biomarker was associated with the occurrence of AF (hazard
ratio [HR], 1.10-1.11). Inflammatory scores of 1, 2, and 3
were independently associated with a progressively higher risk
of AF (HRs 1.37, 1.49, and 1.68, respectively).
Conclusions: Biomarkers of inflammation are independently
associated with the onset of AF in women.
Perspective: There is mounting evidence that inflammation
plays a role in new-onset AF, AF after open-heart surgery,
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Conclusions: Device implantation in the setting of a therapeu-
tic INR is safer than withholding warfarin, either with or
without bridging therapy.
Perspective: This study adds to the literature indicating than
heparin is more likely than warfarin to cause bleeding com-
plications after device implantation. Uninterrupted warfarin
therapy is associated with a lower risk of thromboembolic
complications after both device implantation and radiofre-
quency catheter ablation of atrial fibrillation. Therefore,
there is little rationale for interrupting warfarin therapy in
at-risk patients undergoing an electrophysiologic procedure.  
Summary written by: Fred Morady, MD
Cardiovascular Surgery
Outcomes in Patients With De Novo Left Main
Disease Treated With Either Percutaneous
Coronary Intervention Using Paclitaxel-Eluting
Stents or CABG Treatment in the Synergy Between
Percutaneous Coronary Intervention With TAXUS
and Cardiac Surgery (SYNTAX) Trial
Morice MC, Serruys PW, Kappetein AP, et al.
Circulation 2010;121:2645–2653.
Study Question: What are the outcomes in the prespecified
subgroup of patients with left main (LM) disease in the
SYNTAX trial?
Methods: This observational hypothesis-generating analysis
reports the results of a prespecified powered subgroup of 705
randomized patients who had LM disease among the 1,800
patients with de novo three-vessel disease and/or LM disease
randomized to percutaneous coronary intervention (PCI) with
paclitaxel-eluting stents or coronary artery bypass grafting
(CABG) in the SYNTAX trial.
Results: Major adverse cardiac and cerebrovascular event rates
at 1 year in LM patients were similar for CABG and PCI
(13.7% vs. 15.8%; p = 0.44). At 1 year, stroke was signifi-
cantly higher in the CABG arm (2.7% vs. 0.3%; p = 0.009),
whereas repeat revascularization was significantly higher in
the PCI arm (6.5% vs. 11.8%; p = 0.02); there was no differ-
ence between groups for other endpoints. For anatomic
complexity, those with higher baseline SYNTAX scores had
significantly worse outcomes with PCI than patients with
low or intermediate SYNTAX scores; outcomes for patients
with CABG did not correlate with baseline SYNTAX score,
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Results: The incidence of stroke and transient ischemic attack
was significantly lower in group III (0%) than in groups I
(1.1%) or II (0.9%). There was no significant difference in the
risk of cardiac tamponade between the patients on or off war-
farin (0.3% and 0.2%, respectively) or in the risk of major
bleeding complication between the three groups (0.4, 0.8, and
0.4%, respectively). The mean amount of pericardial drainage
was significantly higher in patients on warfarin (1,200 cc)
than off warfarin (700 cc).
Conclusions: A therapeutic INR during RFCA of AF reduces
the risk of cerebral thromboembolic complications without
increasing the risk of cardiac tamponade or major bleeding
complications.
Perspective: This important study demonstrates that main-
taining a therapeutic INR with warfarin during RFCA of
AF improves the safety profile of the procedure. The impact
of warfarin on the amount of pericardial drainage can be
minimized by emergent infusion of factor VII (not used in
this study).  
Summary written by: Fred Morady, MD
Continuing Warfarin Therapy Is Superior to
Interrupting Warfarin With or Without Bridging
Anticoagulation Therapy in Patients Undergoing
Pacemaker and Defibrillator Implantation
Ahmed I, Gertner E, Nelson WB, et al.
Heart Rhythm 2010;7:745–749.
Study Question: Is therapy with warfarin safer than heparin in
patients undergoing device implantation?
Methods: This was a retrospective analysis of 459 patients
(mean age 71 years) being treated with warfarin who were
referred for device implantation. Patients were managed in
one of three ways: group I, warfarin not withheld and inter-
national normalized ratio (INR) 2-3.5 during the
perioperative period; group II, warfarin discontinued 3-5
days before implantation and heparin bridging therapy used;
group III, warfarin discontinued 3-5 days before implanta-
tion and no bridging therapy used. Warfarin therapy was
restarted in groups II-III the evening of implantation.
Results: The mean INRs during device implantation were
2.6, 1.3, and 1.4 in groups I, II, and III, respectively. Pocket
hematomas occurred more frequently in group II (5.7%)
than group I (0.4%) or III (1.8%). Transient ischemic
attacks occurred more often in group III (3.5%) than group
I (0%) or II (0.8%). Hospitalization was significantly longer
in group II (2.3 days) than group I or II (1.2 days each).
Perspective: This review demonstrated that although trans-
catheter aortic valve implantation success rate is high, there
is a potential for serious complications. Note that the proce-
dural and short-term outcomes appeared to be improving in
more recent studies with an accumulating number of
patients. At this time, transcatheter aortic valve implanta-
tion should be considered only within the boundaries of
clinical trials with special arrangements for clinical gover-
nance, consent, and audit.   
Summary written by: Debabrata Mukherjee, MD
Surgical Management of Descending Thoracic
Aortic Disease: Open and Endovascular
Approaches. A Scientific Statement From the
American Heart Association 
Coady MA, Ikonomidis JS, Cheung AT, et al., on behalf of the
American Heart Association Council on Cardiovascular Surgery and
Anesthesia and Council on Peripheral Vascular Disease.
Circulation 2010;121:2780–2804.
Perspective: The following are 10 points to remember from
the American Heart Association (AHA) Scientific
Statement on surgical management of descending thoracic
aortic disease (TAD). 
1. Descending TAD is increasingly recognized, composed of
distinct etiologies with predictable and well defined clinical
behaviors.
2. Historically, surgical intervention for descending TAD
has been associated with high rates of paraplegia and mor-
tality. However, in recent years, mortality (4-9%) and
paraplegia (<3%) rates have improved.
3. Endovascular thoracic aortic stent grafts are an attractive
treatment option in descending TAD due to lower pub-
lished risks of mortality and paraplegia, particularly in the
high surgical risk groups.
4. Though technically feasible in a variety of clinical settings,
some considerations for the broad application of stent graft-
ing in descending TAD include: 
• Lack of long-term data on durability (>5 years). 
• Lack of prospective randomized trials to directly 
compare open and endovascular therapy. 
• Re-intervention rates, primarily for endoleak, are not 
insignificant. 
• Risk of stroke approaches 4%. 
Conclusions: Patients with LM disease who had revascular-
ization with PCI had safety and efficacy outcomes
comparable to CABG at 1 year.
Perspective: These results are consistent with findings of the
only other randomized LM trial to compare PCI to CABG,
the LE MANS Study (J Am Coll Cardiol 2008;51:538–45).
Note that follow-up in this study was available only through 1
year and it is possible that, with time, differences in outcomes
between patients treated with CABG versus PCI may begin
to emerge. Longer term follow-up and additional prospective
studies are required to determine whether these two revascu-
larization strategies offer comparable outcomes.  
Summary written by: Debabrata Mukherjee, MD
Transcatheter Aortic Valve Implantation for High-
Risk Patients With Severe Aortic Stenosis: A
Systematic Review 
Yan TD, Cao C, Martens-Nielsen J, et al.
J Thorac Cardiovasc Surg 2010;139:1519–1528.
Study Question: What is the safety and clinical effectiveness of
transcatheter aortic valve implantation for patients at high sur-
gical risk with severe aortic stenosis?
Methods: Electronic searches were performed in six databases
from January 2000 to March 2009. Endpoints included fea-
sibility, safety, efficacy, and durability. Clinical effectiveness
was synthesized through a narrative review with full tabula-
tion of results of all included studies.
Results: The current evidence on transcatheter aortic valve
implantation for aortic stenosis is limited to short-term
observational studies. The overall procedural success rates
ranged from 74% to 100%. The incidence of major adverse
events included 30-day mortality (0-25%), myocardial
infarction (0-15%), cardiac tamponade (2-10%), stroke (0-
10%), conversion to surgery (0-8%), moderate to major
paravalvular leak (4-35%), vascular complication (8-17%),
and valve-in-valve procedure (2-12%). The overall 30-day
major adverse cardiovascular and cerebral events ranged
from 3% to 35%. The mean aortic valve area ranged from
0.5 to 0.8 cm2 before and 1.3 to 2.0 cm2 after transcatheter
aortic valve implantation. The mean pressure gradient
ranged from 34 to 58 mm Hg before and 3 to 12 mm Hg
after transcatheter aortic valve implantation. Death rate at 6
months postprocedure ranged from 18% to 48%. 
Conclusions: Use of transcatheter aortic valve implantation
should be considered only within the boundaries of clinical
trials.




• Frequent need for left subclavian bypass procedures 
to secure adequate landing zones.
5. Patients with the Marfan syndrome or other connective
tissue diseases were excluded from stent-graft trials and are
not ideal candidates for stent grafting.
6. Stent graft therapy of thoracic aortic aneurysm should not
be performed at aortic sizes smaller than what is recom-
mended for traditional surgery. Patient selection should be
based on lack of candidacy for open surgery, life expectancy,
and anatomic suitability.
7. Traditional surgery for complicated acute type B dissection
carries significant morbidity and mortality. Endovascular ther-
apy is emerging as an alternative with high technical success,
false lumen thrombosis, and low complication rates.
8. Prophylactic stent grafting to prevent complications of
chronic type B dissection is compared to medical manage-
ment in the INSTEAD and ABSORB trials, but long-term
data are not yet available.
9. Stent grafting can be performed as an alternative to high-
risk surgery in intramural hematoma and penetrating
atherosclerotic ulcers (PAUs) in the descending aorta. Stent
grafting of PAU is associated with higher complication rates
and risk of endoleak is higher. 
10. Treatment of traumatic aortic transaction with stent grafts
is an alternative to surgery in high-risk cases. However, in
this younger population, questions remain regarding graft
durability, impact of frequent imaging, radiation exposure,
and long-term consequences of left subclavian coverage.
Summary written by: Anna M. Booher, MD
General Cardiology
Bleeding Complications With Dual Antiplatelet
Therapy Among Patients With Stable Vascular
Disease or Risk Factors for Vascular Disease.
Results From the Clopidogrel for High
Atherothrombotic Risk and Ischemic Stabilization,
Management, and Avoidance (CHARISMA) Trial
Berger PB, Bhatt DL, Fuster V, et al., on behalf of the CHARISMA
Investigators.
Circulation 2010;121:2575–2583.
Study Question: What are the incidence, implication, and out-
comes associated with dual antiplatelet therapy (DAPT)? 
Methods: The authors analyzed the outcome of patients
enrolled in the CHARISMA trial who were randomized to
DAPT. CHARISMA randomized patients with established
stable vascular disease or multiple risk factors for vascular dis-
ease without established disease, to either aspirin or aspirin
plus clopidogrel. Severe bleeding was defined by the GUSTO
trial criteria, and comprised of fatal bleeding and intracranial
hemorrhage, or bleeding causing hemodynamic compromise
requiring blood or fluid replacement, inotropes, or surgery.
Moderate bleeding was defined as bleeding requiring transfu-
sion, but not meeting any of the severe bleeding criterion.
Results: Randomization to clopidogrel was associated with an
increase in bleeding with severe bleeding occurring in 1.7% of
the clopidogrel group versus 1.3% on placebo (p = 0.087), and
moderate bleeding in 2.1% versus 1.3%, respectively (p <
0.001). The most common site of bleeding was gastrointesti-
nal, followed by intracranial and bleeding related to surgical
procedures. The risk of bleeding was greatest in the first year
and patients who did not suffer moderate or severe bleeding
during the first year were no more likely than placebo-treated
patients to have bleeding subsequently. Moderate bleeding was
a strong predictor of subsequent all-cause mortality (hazard
ratio, 2.55; p < 0.0001).
Conclusions: Use of DAPT is associated with an increased
risk of bleeding, with the incremental risk associated with
DAPT being concentrated in the first year.
Perspective: This important paper provides key data on long-
term bleeding risk in patients on DAPT. The incremental
risk of severe bleeding with DAPT versus aspirin alone was
0.4% and 0.8% with respect to moderate bleeding. Further,
the additive risk of bleeding was concentrated in the first year.
These data should be of immense help to physicians and
patients weighing the risk–benefit ratio of DAPT.  
Summary written by: Hitinder S. Gurm, MBBS
Population Trends in the Incidence and Outcomes
of Acute Myocardial Infarction 
Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS.
N Engl J Med 2010;362:2155–2165. 
Study Question: Have trends in the incidences and outcomes
related to acute myocardial infarction (AMI) changed in
recent times?
Methods: Data from Kaiser Permanente Northern California, a
large, community-based population of patients hospitalized for
AMI, were used for the analysis. Patients were included if
they were 30 years or older and experienced an AMI between
1999 and 2008. Patient characteristics, outpatient medications,
and cardiac biomarker levels were identified from health plan
databases. Outcomes of interest were age- and sex-adjusted
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Methods: A total of 65 patients (ages 18-85 years) with coro-
nary artery disease, a positive exercise tolerance test, and
stable chronic angina pectoris were recruited into a double-
blind, randomized, placebo-controlled, crossover study
conducted in the United Kingdom. Patients were assigned
to allopurinol (week 1, 100 mg/d; week 2, 300 mg/d; then
300 mg twice daily) or placebo for 6 weeks before crossover.
Results: Mean age was 64 years and 83% were men; 70% were
Canadian Cardiovascular Society (CCS) angina class II, and
15% CCS I and III; 84% had ≥2-vessel disease and 85% had
normal left ventricular ejection fraction. Concomitant
antianginal treatment: 87% beta-blockers, 58% nitrates, 22%
calcium channel blockers, and 22% nicorandil. Allopurinol
increased the median time to ST depression to 298 s from a
baseline of 232 s, and placebo increased it to 249 s (p =
0.0002). The point estimate (absolute difference between
allopurinol and placebo) was 43 s. Allopurinol increased
median total exercise time to 393 s from a baseline of 301 s,
and placebo increased it to 307 s (p = 0.0003); the point esti-
mate was 58 s. Allopurinol increased the time to chest pain
from a baseline of 234 s to 304 s, and placebo increased it to
272 s (p = 0.001); the point estimate was 38 s. No adverse
effects of treatment were reported.
Conclusions: Allopurinol seems to be a useful, inexpensive,
well-tolerated, and safe anti-ischemic drug for patients with
angina.
Perspective: The absolute increase in median time to ST
depression with allopurinol of 43 s (10% increase) is similar
to classic antianginal drugs. Inhibiting xanthine oxidase with
allopurinol has been shown to decrease myocardial oxygen
demand per unit of cardiac output, improve endothelial
function, and reduce afterload. The results are impressive in
light of the use of beta-blockers in 87%. The safety and effi-
cacy of allopurinol need to be assessed in a much larger
cohort. This very inexpensive generic drug could reduce the
need for revascularization, improve quality of life, and
reduce coronary events.  
Summary written by: Melvyn Rubenfire, MD, FACC
Interventional Cardiology
Radiation Safety Among Cardiology Fellows 
Kim C, Vasaiwala S, Haque F, Pratap K, Vidovich MI.
Am J Cardiol 2010;May 17:2010;106:125–128. 
Study Question: What is the current level of fellow training
with respect to radiation exposure minimization and manage-
ment?
incident rates of AMI, ST-elevation myocardial infarction
(STEMI), and non-STEMI (NSTEMI).
Results: A total of 46,086 hospitalizations for AMI over
18,691,131 person-years of follow-up were included. The
majority of AMIs were NSTEMIs (66.9%) and 33.1% were
STEMIs. The proportion of STEMIs decreased over time,
from 47% to 22.9%. Age- and sex-adjusted incidence of MI
increased from 274 cases per 100,000 person-years in 1999 to
287 cases per 100,000 person-years in 2000, after which a
decline was observed to 208 cases per 100,000 person-years in
2008, representing a 24% relative decrease. For STEMI, both
age- and sex-adjusted incident rate decreased from 133 cases
per 100,000 person-years in 1999 to 50 cases per 100,000 per-
son-years in 2008. The incidence of NSTEMI increased from
155 cases per 100,000 person-years in 1999 to 202 cases per
100,000 person-years in 2004, after which rates decreased. In
more recent years, patients hospitalized with AMI were more
likely to be older, female, and have coexisting illness. The
number of patients who underwent revascularization proce-
dures within 30 days after AMI increased from 40.7% in 1999
to 47.2% in 2008. For STEMI, the revascularization increased
from 49.4% to 69.6%. For NSTEMI, revascularization
increased from 33.4% to 41.3%. Age- and sex-adjusted 30-day
mortality decreased from 10.5 in 1999 to 7.8% in 2008.
Conclusions: In this population, the incidence of AMI has
decreased over time with a significant reduction in the inci-
dence of STEMI as well as a lower death rate after NSTEMI.
Potential factors related to the decline in AMI rates include
smoking bans, and improved management of blood pressure
and lipids.
Perspective: These data demonstrated an encouraging trend
in the reduction of AMI. However, continued efforts to pre-
vent AMI, in particular NSTEMI, are warranted. Given the
prevalence of obesity and related cardiac risk factors such as
hypertension and diabetes mellitus, continued aggressive
prevention measures combined with monitoring of popula-
tion trends are needed.  
Summary written by: Elizabeth A. Jackson, MD
Effect of High-Dose Allopurinol on Exercise in
Patients With Chronic Stable Angina: 
A Randomised, Placebo Controlled Crossover Trial 
Noman A, Ang DS, Ogston S, et al.
Lancet 2010;375:2161–2167.
Study Question: Does high-dose allopurinol prolong exercise
capability in patients with chronic stable angina?




Methods: The authors invited 2,545 general and subspecialty
cardiology fellows to participate in a survey on knowledge and
practice of radiation safety.
Results: Of the 267 respondents (10.5% return rate), 82% had
undergone formal radiation safety training. Approximately
60% of the fellows were aware of their hospital’s pregnancy
radiation policy and knew how to contact the hospital’s radia-
tion safety officer. Over half (52%) of the fellows always wore
a dosimeter, yet most (81%) did not know their level of radia-
tion exposure in the previous year. Formal training was
associated with a greater awareness of institutional radiation
pregnancy policy, knowledge of contact information of the
radiation safety officer, awareness of safe levels of radiation
exposure, and consistent use of dosimeters and RadPads.
Conclusions: There are significant lacunae in the education of
cardiology fellows with respect to radiation safety.
Perspective: This survey, despite its small sample, raises real
concerns. Lack of fellow education likely results in increased
radiation exposure to the fellows, patients, and others
involved in the procedure. Hopefully this paper will lead to
fellowship programs across the country examining their
radiation safety education and rectifying the shortcomings
that may exist therein.  
Summary written by: Hitinder S. Gurm, MBBS
Interventional Cardiology
Association Between Use of Bleeding Avoidance
Strategies and Risk of Periprocedural Bleeding
Among Patients Undergoing Percutaneous
Coronary Intervention
Marso SP, Amin AP, House JA, et al.
JAMA 2010;303:2156–2164.
Study Question: What is the association between the use of
two bleeding avoidance strategies, vascular closure devices
and bivalirudin, and post–percutaneous coronary interven-
tion (PCI) bleeding rates in a nationally representative PCI
population?
Methods: This was an analysis of data from 1,522,935
patients undergoing PCI procedures performed at 955 US
hospitals participating in the National Cardiovascular Data
Registry (NCDR) CathPCI Registry from January 1, 2004,
through September 30, 2008. This registry is jointly spon-
sored by the American College of Cardiology (ACC) and
the Society for Cardiovascular Angiography and
Interventions. The primary outcome was periprocedural
bleeding.
Results: Bleeding occurred in 30,654 patients (2%). Manual
compression, vascular closure devices, bivalirudin, or vascular
closure devices plus bivalirudin were used in 35%, 24%, 23%,
and 18% of patients, respectively. Bleeding events were
reported in 2.8% of patients who received manual compres-
sion, compared with 2.1%, 1.6%, and 0.9% of patients
receiving vascular closure devices, bivalirudin, and both
strategies, respectively (p < 0.001). Bleeding rates differed by
preprocedural risk assessed with the NCDR bleeding risk
model (low risk, 0.72%; intermediate risk, 1.73%; high risk,
4.69%). In high-risk patients, use of both strategies was asso-
ciated with lower bleeding rates (manual compression, 6.1%;
vascular closure devices, 4.6%; bivalirudin, 3.8%; vascular clo-
sure devices plus bivalirudin, 2.3%; p < 0.001). Both strategies
were used least often in high-risk patients (14.4% vs. 21.0% in
low-risk patients, p < 0.001).
Conclusions: Vascular closure devices and bivalirudin were
associated with significantly lower bleeding rates, particularly
among patients at greatest risk for bleeding.
Perspective: These findings emphasize the need for additional
research to better understand why higher-risk patients are
least likely to receive bleeding avoidance strategies but also
suggest the need to test interventions to overcome the risk-
treatment paradox, such as directing bleeding avoidance
strategies to high-risk patients by providing preprocedural
estimates of post-PCI bleeding. Quality improvement tools
developed by the ACC NCDR are already helping with rapid
adoption of bleeding avoidance and other quality initiative
strategies by the cardiovascular community.  
Summary written by: Debabrata Mukherjee, MD
Prevention/Vascular 
Effects of Fibrates on Cardiovascular Outcomes: 
A Systematic Review and Meta-Analysis
Jun M, Foote C, Lv J, et al.
Lancet 2010;375:1875–1884.
Study Question: What is the effect of fibrates on major cardio-
vascular outcomes?
Methods: A systematic review and meta-analysis was used to
investigate the effects of fibrates on major clinical outcomes.
Eighteen trials provided data for 45,058 participants, includ-
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ing 2,870 major cardiovascular events, 4,552 coronary events,
and 3,880 deaths. Eight studies enrolled only men, and six
were undertaken in diabetics. Secondary prevention was the
goal of 11 studies, primary prevention in four, and the
remainder included patients with and without a previous his-
tory of cardiovascular disease. Eight studies had specific lipid
profile requirements for trial entry.
Results: Data for the effects of fibrate therapy on major cardio-
vascular events were available from five trials, including
19,944 participants and 2,870 cardiovascular events. The
mean age ranged between 46 and 68 years. Overall, fibrate
therapy produced a 10% relative risk (RR) reduction (95%
confidence interval, 0-18) for major cardiovascular events (p =
0.048) and a 13% RR reduction (7-19) for coronary events (p
< 0.0001), but had no benefit on stroke (p = 0.69). There was
no effect of fibrate therapy on the risk of all-cause mortality (p
= 0.92), cardiovascular mortality (p = 0.59), sudden death (p =
0.19), or nonvascular mortality (p = 0.063). Fibrates signifi-
cantly reduced the risk of albuminuria progression and
retinopathy. Serious drug-related adverse events were not sig-
nificantly increased by fibrates, although increases in serum
creatinine concentrations were common (p < 0.0001). 
Conclusions: Fibrates can reduce the risk of major cardiovas-
cular events predominantly by prevention of coronary events,
and might have a role in individuals at high risk of cardio-
vascular events and in those with combined dyslipidemia.
Perspective: The role of fibrates, specifically fenofibrate, in dia-
betics and nondiabetics with and without coronary disease is
not much clearer because of this meta-analysis. Statins are the
drug of choice regardless of the lipid phenotype. It is reason-
able to consider fibrates for primary and secondary prevention
in persons with statin intolerance, preferably in combination
with nonstatin lipid-lowering agents that lower the low-den-
sity lipoprotein cholesterol.  
Summary written by: Melvyn Rubenfire, MD
Diabetes Mellitus, Fasting Blood Glucose
Concentration, and Risk of Vascular Disease: 
A Collaborative Meta-Analysis of 102 Prospective
Studies
The Emerging Risk Factors Collaboration.
Lancet 2010;375:2215–2222.
Study Question: What are the risks associated with diabetes and
blood glucose concentrations associated with vascular disease?
Methods: This was a meta-analysis using records of diabetes,
fasting blood glucose concentration, and other risk factors in
people without initial vascular disease. All studies were from
the Emerging Risk Factors Collaboration. Combined within-
study regressions adjusted for age, sex, smoking, systolic
blood pressure, and body mass index were used to calculate
hazard ratios for vascular disease.
Results: A total of 698,782 people from 102 prospective
studies were included. The mean age of the study popula-
tion was 52 years and 43% were women. Nonfatal and fatal
vascular outcomes occurred in 52,765 subjects over 8.49
million person-years of risk.  The adjusted risk of diabetes
was 2.00 for coronary heart disease; 2.27 for ischemic
stroke; 1.56 for hemorrhagic stroke; 1.84 for unclassified
stroke; and 1.73 for the aggregate of other vascular deaths.
Risk was higher among women compared to men, and for
fatal versus nonfatal events. The adult population-wide
prevalence of 10% diabetes was estimated to account for
11% of vascular deaths. Fasting glucose was associated with
vascular risk in a nonlinear fashion. For higher levels of fast-
ing glucose, increased risk of vascular disease was observed;
for fasting glucose between 5.60 mmol/L and 6.09 mmol/L,
the hazard ratio (HR) was 1.11; and for a fasting glucose
between 6.10 mmol/L and 6.99 mmol/L, the HR was 1.17.
Conclusions: Diabetes increases risk for vascular disease
approximately twofold, independent of other risk factors.
Among subjects without diabetes, fasting blood glucose is
modestly and nonlinearly associated with risk of vascular
disease.
Perspective: These findings from a large set of prospective
studies support the understanding that diabetes significantly
increases a patient’s risk for vascular events. It is interesting
that fasting glucose among diabetics does not add prognos-
tic information beyond traditional risk factors. Prevention of
diabetes and higher fasting glucose levels to prevent vascular
disease is likely more effective than glucose control once
diabetes has developed.  
Summary written by: Elizabeth A. Jackson, MD
White Rice, Brown Rice, and Risk of Type 2
Diabetes in US Men and Women
Sun Q, Spiegelman D, van Dam RM, et al.
Arch Intern Med 2010;170:961–969.
Study Question: Is rice consumption associated with risk of
type 2 diabetes?
Methods: Subjects enrolled in three prospective cohorts were
used for the analysis. Men from the Health Professionals




Follow-up Study (age range, 32-87 years) were included, in
addition to women from the Nurses’ Health Study (age range,
26-45 years) and Nurses’ Health Study II (age range, 26-45
years). Five categories of white rice intake were created, rang-
ing from <1 serving per month, to ≥5 servings per week.
Three categories of brown rice were created, ranging from
<1 serving per month to ≥2 servings per week. 
Results: A total of 39,765 men and 157,463 women were
included. Over 20 years of follow-up, 2,648 cases of type 2
diabetes were observed in the Health Professionals Follow-
up Study cohort. In the original Nurses’ Health Study
cohort, 5,550 cases were observed over 22 years of follow-
up, and in the Nurses’ Health Study II cohort, 2,359 cases
were observed during 14 years of follow-up. After adjust-
ment for age, diet, and lifestyle factors such as physical
activity, intake of white rice (≥5 servings per week vs. <1
per month) was associated with a higher risk for type 2 dia-
betes. The pooled relative risk was 1.7. In contrast, intake
of brown rice appeared protective, with a relative risk of
0.89 for high intake (≥2 servings per week) compared to
low intake (<1 serving per month). Replacing 50 g/day of
white rice in the diet with the same amount of brown rice
was estimated to lower the risk of type 2 diabetes by 16%.
The same replacement of whole grains as a group was esti-
mated to be associated with a 36% lower risk for type 2
diabetes.
Conclusions: Substitution of whole grains, including brown rice
for white rice, lowers risk of type 2 diabetes.
Perspective: These findings provide further evidence for rec-
ommending whole grains (including brown rice) to patients
at risk for diabetes. Dietary changes can have a significant
impact on cardiovascular disease prevention; health care
providers can use findings from studies such as this to edu-
cate their patients regarding healthy dietary practices.  
Summary written by: Elizabeth A. Jackson, MD
Effects of Homocysteine-Lowering With Folic Acid
Plus Vitamin B12 vs. Placebo on Mortality and Major
Morbidity in Myocardial Infarction Survivors: 
A Randomized Trial
Study of the Effectiveness of Additional Reductions in Cholesterol
and Homocysteine (SEARCH) Collaborative Group.
JAMA 2010;303:2486–2494.
Study Question: Does supplementation with folic acid and
vitamin B12 reduce homocysteine levels and improve mortal-
ity and morbidity among patients after myocardial infarc-
tion (MI)? 
Methods: Mailed invitations to 83,237 men and women (ages
18-80 years) who were survivors of an MI resulted in 34,780
potential subjects attending screening exams. A total of
12,064 participants were enrolled in the study between
September 1998 and October 2001. The intervention group
received 2 mg of folic acid plus 1 mg of vitamin B12, whereas
the control group received matching placebo. Primary out-
comes of interest were first major vascular event, defined as
major coronary events (coronary death, MI, or coronary
revascularization), fatal or nonfatal stroke, or noncoronary
revascularization.
Results: Homocysteine levels were reduced by an average of
3.9 μmol/L (28%). During the 6.7 years of follow-up, major
vascular events occurred in 1,537 participants who were ran-
domized to folic acid and vitamin B12, and 1,493 of
participants randomized to placebo (25.5% vs. 24.8%). The
relative risk (RR) of intervention was not significantly differ-
ent from placebo (RR, 1.04). No significant effects of folic
acid and vitamin B12 were observed for major coronary
events (RR, 1.05), stroke (RR, 1.02), or noncoronary revas-
cularization (RR, 1.18). No significant differences were
observed between the two groups for vascular death, nonvas-
cular deaths, or incident cancers.
Conclusions: Folic acid with vitamin B12 reduced homocys-
teine levels, but did not reduce vascular outcomes.
Supplementation was not associated with increased cancer
incidence.
Perspective: Given the billion dollar supplement industry,
these data suggest that folic acid with vitamin B12 does not
provide protection against vascular events for secondary
events. These data add to other data that suggest patients
may avoid increasing health care costs by not buying such
supplements.  
Summary written by: Elizabeth A. Jackson, MD
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